REFERENCES
- Broman E., Khoo C., Taylor L. S. A comparison of alternative polymer excipients and processing methods for making solid dispersions of poorly water-soluble drug. Int. J. Pharm. 2001; 222: 139–151
- Edward J. O. C. Review of the Unique Properties of budesonide. Clin. Ther. 2003; 25: C42–C60
- Greenhalgh D. J., Williams A. C., Timmins P., York P. Solubility parameters as predictors of miscibility in solid dispersions. J. Pharm. Sci. 1999; 88: 1182–1190
- Hou S., Handle M., Byron P. R. A stability-indicating HPLC assay method for budesonide. J. Pharm. Biomed. Anal. 2001; 24: 371–380
- Kim C. J. Effects of drug solubility, drug loading, and polymer molecular weight on drug release from polyox tablets. Drug Dev. Ind. Pharm. 1998; 24: 645–651
- Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000; 50: 47–60
- Löbenberg R., Amidon G. L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 2000; 50: 3–12
- Martin T. A., Bandi N., Schulz R., Roberts C. B., Kompella U. B. Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology. AAPS Pharm. Sci. Tech. 2002; 3: 1–11
- Mehta K. A., Kislalioglu M. S., Phuapradit W., Malick A. W., Shah N. H. Muliti-unit controlled release systems of nifedipine and nifedipine:pluronic F-68 solid dispersion: characterization of release mechanisms. Drug Dev. Ind. Pharm. 2002; 28: 275–285
- Mishim K., Tokuyasu T., Matsuyama K., Komorita N., Enjoji T., Nagatani M. Solubility of polymer in the mixtures containing supercritical carbon dioxide and antisolvent. Fluid Phase Equilibria. 1998; 144: 299–305
- Moneghini M., Kikic I., Voinovich D., Perissutti B., Filipovic-Grcic J. Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterization, and in vitro dissolution. Int. J. Pharm. 2001; 222: 129–138
- Mutlu E. A., Farhadi A., Keshavarzian A. New developments in the treatment of inflammatory bowel disease. Expert Opin. Investig. Drugs 2002; 11: 365–385
- Nijlen T. V., Brennan K., Van den Mooter G., Blaton N., Kinget R., Augustijns P. Improvement of the dissolution rate of artemisinin by means of supercritical fluid technology and solid dispersions. Int. J. Pharm. 2003; 254: 173–181
- Ozeki T., Yuasa H., Kanaya Y. Application of the solid dispersion method to the controlled release of medicine.□. Difference in the release of flurbiprofen from solid dispersions with poly(ethylene oxide) and hydroxypropylcellulose and the interaction between medicine and polymers. Int. J. Pharm. 1997; 155: 209–217
- Pearlman D. S. Preclinical Properties of Budesonide: Translation to the Clinical Setting. Clin. Ther. 2003; 25: C75–C91
- Schachter M. D., Xiong J., Tirol G. C. Solid state NMR perspective of drug–polymer solid solutions: a model system based on poly(ethylene oxide). Int. J. Pharm. 2004; 281: 89–101
- Serajuddin A. T. M. Solid dispersions of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999; 88: 1058–1066
- Sethia S., Squillante E. Solid dispersions: revival with greater possibilities and applications in oral drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2003; 20: 215–247
- The Dow Chemical Company. POLYOX Water-Soluble Resins NF in Pharmaceutical Applications Brochure. Form No. 326-00013-0802, 2002
- Vemavarapu C., Mollan M. J., Lodaya M., Needhamb T. E. Design and process aspects of laboratory scale SCF particle formation systems. Int. J. Pharm. 2005; 292: 1–16
- Weidner E., Wiesmet V., Knez Z., Skerget M. Phase equilibrium (solid-liquid-gas) in polyethyleneglycol-carbon dioxide. J. Supercrit. Fluids 1997; 10: 139–147